The mixed lineage leukemia (MLL) proteins regulate an array of developmental and differentiation processes. Similar to other members of the SET1 family, association of MLL1-4 with Ash2L, RbBP5 and WDR5, collectively termed the MLL core complex, is required for MLL mediated histone H3 Lys-4 di/tri-methylation. Each member of the core complex has a unique role in modulating the activity of MLL1. WDR5 is key in nucleating the formation of the core complex by acting as a structural scaffold, whereas Ash2L and RbBP5 are responsible for stimulating MLL methyltransferase activity. Currently, the structural and biochemical mechanisms utilized by the core complex to regulate MLL1 activity are unknown. Through structural and biochemical dissection of the core complex we have assigned specific functions to core complex subunits and have identified the minimal structural requirements for methyltransferase activity. Furthermore, through structure based drug design, we have identified a peptidomimetic inhibitor of MLL1 methyltransferase activity.

No description available.

Splicing is the process when introns gets removed and exons are spliced together. This is an important step to form a clean mRNA with no unnecessary sequences that could interrupt protein synthesis. There are different types of splicing and some of them need a complex called spliceosome. The spliceosome requires ATP, small nuclear RNAs and splicing factors. The spliceosome and the process splicing can be regulated by epigenetics, and one epigenetic mechanism is histone modification. There are four types of histone modifications; methylation, phosphorylation, ubiquitination and acetylation. They regulate splicing to different extents by altering the chromatin structure, affect the assembly of the spliceosome and regulate the attraction of splicing factors. This review will investigate if histone modifications affect splicing and to what extent. Suggestions for further research regarding the relationship between splicing and histone modifications will also be provided. The review is based on 30 articles and two books and the search was conducted between 30th of March 2020 and 13th of April 2020. Ubiquitination and phosphorylation have a minor effect on splicing meanwhile methylation and acetylation affect splicing in great extent.

Les mécanismes épigénétiques jouent un rôle essentiel dans la régulation de l’expression des gènes. L’enzyme du complexe répresseur Polycomb II EZH2, capable de triméthyler la lysine 27 de l’histone H3 (H3K27me3) est impliquée dans la régulation de nombreux processus normaux, tels que le développement et la différenciation cellulaire. Les plasmocytes jouent un rôle majeur dans la réponse immunitaire humorale. La différenciation des lymphocytes B en plasmocytes (PCD) est finement régulée par un réseau de facteurs de transcription impliqué de l’induction et le maintien de l’identité de ces deux types cellulaires. Par ailleurs, peu de mécanismes épigénétiques ont été décrits dans la PCD. En utilisant un modèle in vitro de PCD développé dans notre laboratoire, nous avons mis en évidence une surexpression d’EZH2 dans le stade préplasmablaste (prePB) de la PCD. Grâce à l’analyse globale des séquences d’ADN associées à EZH2 et H3K27me3 dans ce type cellulaire, nous avons montré que l’enzyme était capable de réprimer l’expression de gènes impliqués dans différentes fonctions des lymphocytes B et des plasmocytes. EZH2 est également capable de se fixer sur le promoteur de gènes actifs dans les prePB, impliqués dans la régulation de la prolifération de ces cellules. En outre, nous avons montré que l’inhibition chimique d’EZH2 dans notre modèle résultent en une dérégulation transcriptionnelle associée à une accélération du processus de différenciation. Nos résultats suggèrent qu’EZH2 est impliqué dans le maintien de l’état transitoire, immature et prolifératif des prePBs via la régulation de gènes, dépendante et indépendante de H3K27me3, favorisant l’amplification des cellules à défaut de leur différenciation en plasmocytes. Des anomalies de séquence ou de l’expression d’EZH2 ont été mis en évidence de nombreux cancers hématologiques et solides. Le myélome multiple (MM) est une hémopathie caractérisée par l’accumulation de plasmocytes tumoraux dans la moelle osseuse. Nos travaux ont notamment permis d’identifier une surexpression des membres du complexe Polycomb Repressive Complex 2 (PRC2) dans les cellules de MM, en association avec leur prolifération. Afin de comprendre le rôle de PRC2 dans le MM, nous avons utilisé un inhibiteur de l’activité méthyltransférase d’EZH2 (EPZ-6438). L’effet de l’inhibiteur d’EZH2 sur la prolifération et la survie des cellules de MM est très hétérogène. En effet, les cellules sensibles présentent un arrêt du cycle cellulaire et entrent en apoptose. De manière intéressante, la résistance des cellules de MM à l’inhibiteur d’EZH2 pourrait être médiée induite par la méthylation des promoteurs des gènes cibles de PRC2. Nous avons ainsi établi un score (EZ-score), basé sur l’expression des gènes, permettant d’identifier des patients de mauvais pronostic pouvant bénéficier d’un traitement avec un inhibiteur d’EZH2. Nous avons également mis en évidence un effet synergique de EPZ-6438 et du Lenalidomide, un agent immuno-modulateurs utilisé en traitement conventionnelle du MM. Cette inhibition de la croissance cellulaire est notamment due à l’induction de l’expression de facteurs de transcription, spécifiques des lymphocytes B, et des suppresseurs de tumeurs en association avec la répression de l’expression de MYC. Aussi, un prétraitement avec l’inhibiteur d’EZH2 permet de surmonter la résistance des cellules tumorales au Lenalidomide. Ces données suggèrent que le ciblage de PRC2 pourrait avoir un intérêt thérapeutique chez les patients caractérisés par un mauvais pronostic et un fort EZ-score. Ainsi, l’inhibiteur d’EZH2 pourrait également permettre de resensibiliser les patients aux chimiothérapies basées sur des agents immuno-modulateurs. / Epigenetic mechanisms play an essential role in gene expression regulation. EZH2, the catalytic sub-unit of PRC2, is able to trimethylate the lysine 27 of histone H3 (H3K27me3) and is involved in the regulation of numerous normal processes, such as development and cell differentiation. Plasma cells (PCs) play a major role in the defense of the host organism against pathogens, by producing antigen-specific antibodies. B cell differentiation into PC is mediated by a fine-tuned regulatory network of cell specific transcription factors involved in B and plasma cell identity. Although numerous key actors involved in plasma cell differentiation (PCD) have been described, most of the epigenetic mechanisms associated with this process are yet to be unveiled. Using an in vitro model of PCD developed in our laboratory, we showed that EZH2 is upregulated in the preplasmablast stage (prePB) of the PCD. By analyzing DNA sequences associated with EZH2 and H3K27me3 in this cell type, we highlighted that EZH2 is recruited to and represses through H3K27me3 a subset of genes involved in B cell and plasma cell identity. Interestingly, in prePBs and PBs, EZH2 was also found to be recruited to H3K27me3-free promoters of transcriptionally active genes known to regulate cell proliferation and DNA repair. Inhibition of EZH2 catalytic activity resulted in B to PC transcriptional changes associated with PC maturation induction together with higher immunoglobulin secretion. Altogether, our data suggests that EZH2 is involved in the maintenance of prePBs/PBs transitory immature proliferative state through H3K27me3-dependent and independent gene regulation supporting their amplification. Moreover, while EZH2 overexpression was previously shown to inhibit PCD in mice, this study highlights for the first time that EZH2 inhibition can accelerate normal human PCD by prematurely inducing a plasma cell transcriptional program.EZH2 mutations or abnormal expression were shown to be involved in numerous hematological malignancies and solid tumors. Multiple Myeloma (MM) is a malignant plasma cell disease with a poor survival, characterized by the accumulation of myeloma cells (MMCs) within the bone marrow. We identified a significant upregulation of the Polycomb Repressive Complex 2 (PRC2) core genes in MM cells in association with proliferation. We used EPZ-6438, a specific small molecule inhibitor of EZH2 methyltransferase activity, to evaluate its effects on MM cells phenotype and gene expression profile. PRC2 targeting results in cell growth inhibition due to cell cycle arrest and apoptosis together with Polycomb, DNA methylation, TP53 and RB1 target genes induction. EZH2 inhibitor induced toxicity was heterogeneous in human myeloma cell lines and primary MM cells from patients. Interestingly, we found that MM cell resistance to EZH2 inhibitor could be mediated by DNA methylation of PRC2 target genes. We established a gene expression-based EZ-score allowing to identify poor prognosis patients that could benefit from EZH2 inhibitor treatment. We also demonstrated a synergistic effect of EPZ-6438 and Lenalidomide, a conventional drug used for MM treatment, through the activation of B cell transcription factors and tumor suppressor gene expression in concert with MYC repression. Moreover, EPZ-6438 pre-treatment was able to overcome MM cells resistance to lenalidomide. These data suggest that PRC2 targeting could have a therapeutic interest in MM patients characterized by high-risk EZ-score values, reactivating B cell transcription factors and tumor suppressor genes. EZH2 inhibitor could also re-sensitize MM patients to chemotherapies based on immunomodulatory agents.

Methylation of lysine residues in histone tails is an intensively studied epigenetic signal that regulates transcription throughout development. Methylation of histone 3 lysine 4 (H3K4) is usually associated with promoters of actively transcribed genes whereas H3K27 or H3K9 methylation silences genes. Yeast possess only one H3K4 methyltransferase, Set1. In contrast, there are six enzymes capable of catalyzing this modification in mammals implying a certain specialization or division of labor. The present study examined the functions of the mouse H3K4 methyltransferase paralogs, Mixed Lineage Leukemia 1 (Mll1) and Mll2, during neural differentiation and reprogramming of neural stem (NS) cells to induced pluripotency. We could show that Mll2 is required for differentiation of embryonic stem (ES) cells to neural progenitors and identified Nuclear transport factor 2-like export factor 2 (Nxt2) as essential target gene. Mll2 trimethylated the Nxt2 promoter in ES cells in order to allow for transcriptional upregulation during subsequent neural differentiation. Additionally, Mll2 prevented apoptosis of differentiating cells by regulating B cell leukemia/lymphoma 2 (Bcl2) levels. Mll1 could replace Mll2 after the first steps of cell commitment towards epiblast stem (EpiS) cells. While Mll2 activity was only required briefly when ES cells started to differentiate, the influence of Mll1 seemed to increase with developmental progression. It stabilized the NS cell state by regulating expression of the neural transcription factor Orthodenticle homolog 2 (Otx2). Thereby, Mll1 impeded early steps of reprogramming to induced pluripotency and its inactivation increased the efficiency. Besides their specificity for certain target genes, both enzymes also differed in their activity. The major function of Mll1 was to prevent silencing by H3K27 methylation and possibly recruitment of transcription factors. In contrast, Mll2 conducted H3K4 trimethylation of its target genes. Importantly, once established in NS cells, the expression of Nxt2 became independent of promoter H3K4 methylation. Thus, Mll2 and its target gene Nxt2 represent an example for H3K4 methylation functioning as priming mechanism rather than for fine-tuning or maintenance of transcription levels.

Der SET-Bereich befindet sich unter den verschiedenen Proteinsequenzbereichen, die mit epigentischer Regulation hauptsächlich durch die Präsenz von Trihtorax (trxG) und Polycomb (PcG) Gruppen von Chromatinmodifikatoren in Zusammenhang gebracht werden. Nach der Entdeckung des ersten SET-Bereichs vor einigen Jahren, welcher die Histon-Lysin-Methyltransferase (Su(var)39) enthält, wurde den Proteinen mit SET-Bereich sehr viel Aufmerksamkeit geschenkt. Obwohl die Histon-Lysin-Methylierung schon länger als 30 Jahre bekannt ist, war ihre Funktion vor diesem überragenden Ergebnis größten Teils unbekannt. In meiner Arbeit beschreibe ich die kombinatorische und funktionale Charakterisierung von 3 Hefe Proteinkomplexen durch die Anwendung von proteomischer SEAM (Sequential Epitope Tagging and Mass Spectrometry). Zwei dieser Komplex enthalten einen SET-Bereich und die Dritte ist der Rad6 Komplex aus S. pombe (Sp_Rad6C). Der Set1 Komplex (Set1C) beinhaltet 8 Bausteine, methylisiert Lysin 4 in Histon H3 und ist die erste, entdeckte Histone H3 Lysin 4 Methyltransferase. Es beinhaltet ein Ash2 Homolog (Bre2), einen bekannten Baustein von trxG. Kürzlich wurden Rad6 beinhaltende Komplexe gezeigt, die in engem Bezug zu der H3-K4 und H3-K79 Methylation durch ubiquitinierung von Histon H2B und die Etablierung von trans-histonen Signalwegen stehen. Unsere Analysen von Sp-Rad6C führten zu mehreren interessanten Ansichten. Der Set3 Komplex (Set3C) hat keine feststellbare Aktivität einer Methyltransferase, enthält jedoch zwei Histon deacetylasen (HDACs) ? eine klassische HDAC (Hos2) und eine NAD-abhängige HDAC (Hst1). Unsere funktionelle Analyse von Set3C zeigt, dass Set3C bei der Regulierung des meiotischen Genexpressionsprogramms in knospenden Hefen (S. cerevisiae) beteiligt ist. Evolutionbiologisch betrachtet, ist die Spalt-Hefe (S. pombe) sehr weit von S. cerevisiae entfernt und wird meist als ein besserer Modellorganismus fur höhere Eukaryoten angesehen. In einem Versuch, unser Wissen uber andere Organismen zu vergrößern, haben wir ähnliche Untersuchungen in S. pombe unternommen und haben herausgefunden, dass Set1C in beiden Hefen sehr stark konserviert ist. Darüberhinaus waren die Set1-Ash2 Verbindungen konserviert und wir nehmen an, dass auch in höheren Eukaryoten Set1-ahnliche Methyltransferasen Ash2-ahnliche Proteinen angehören. Dies wurde später durch mehrere Studien von anderen Gruppen bestätigt, die an Säugetieren arbeiten. Was Set3C anbelangt, wurden unsere weiteren Analysen nur durch vergleichende Proteomik beschränkt. Wir zeigen, dass der proteomische Kern von Set3C in Spalt-Hefe konserviert wird. Im Gegensatz zu Set3C in S. cerevisiae, beinhaltet diese in S. pombe nur eine HDAC, die zur Hos2 Familie gehört,. Die präsentierte Arbeit hat auch viele Auswirkungen auf die übergreifende Organisation von Proteomen. Wir beschreiben verschiedene Beispiele von gemeinsamen Komponenten zwischen unterschiedlichen Komplexen und prägen den Begriff "proteomischer Hyperlink". Wir waren in der Lage zu zeigen, dass proteomische Kerne sogar für unwesentliche Proteinkomplexe hoch konserviert sind. Die generelle proteomische Schaltung über proteomische Hyperlinks scheint jedoch verworrener und unvorhersehbar zu sein. Wir schlussfolgern, dass die Erschaffung von zuverlässigen, detailierten, proteomischen Abbildungen, welche auf dem Wissen von niederen Organismen fundieren, zur Zeit nicht möglich ist.

DNA methylation and histone modifications have emerged as key mechanisms in transcriptional regulation. The target of methylation-induced silencing 1 (TMS1) is a bipartite protein. Recent studies have indicated that methylation-associated silencing of TMS1 occurs in many cancers. However, whether and how TMS1 is regulated by epigenetic mechanisms in cancers remains unknown. In this study we showed that methylation of the TMS1 promoter occurred in five of six hepatocellular carcinoma (HCC) cell lines. TMS1 expression was reduced in four HCC cell lines and correlated with methylation status. Furthermore, the TMS1 promoter was completely methylated and mRNA expression was undetectable. TMS1 expression could be restored by 5-aza-2′-deoxycitidine (5-Aza-dC) (a DNA methyltransferase inhibitor) or trichostatin A (TSA) (a histone deacetylase inhibitor) alone and the promoter methylation. was partially reversible. TSA was more efficient than 5-Aza-dC in inducing TMS1 expression, and the combination of 5-Aza-dC and TSA resulted in markedly synergistic reactivation of the gene and completely reversed promoter methylation. Interestingly, TMS1 promoter methylation-associated gene silencing was accompanied by histone H3 Lysine 9 (H3K9) hypoacetylation and trimethylation. 5-Aza-dC and/or TSA also had some effect on conversion of methylated to acetylated H3K9 in restoring TMS1. This conversion was dynamic at the TMS1 promoter and a decrease in H3K9 trimethylation preceded an increase in H3K9 acetylation after 5-Aza-dC and/or TSA treatment. Our results thus suggest that epigenetic inactivation of TMS1 expression is regulated by promoter hypermethylation and H3K9 modifications in a coordinated way.

Indiana University-Purdue University Indianapolis (IUPUI) / CXXC finger protein 1 (CFP1) is an epigenetic regulator of H3K4 and cytosine methylation. Due to its role in establishing and maintaining methylation patterns, CFP1 determines whether DNA is found in its euchromatin or heterochromatin state and as such whether genes are transcriptionally active or inactive. In stem cells, deficiency of CFP1 results in inability to differentiate and in murine embryos it results in periimplantation death. Despite the demonstrated importance in developing tissue, the role of CFP1 in mature tissues, such as the liver, has yet to be elucidated. This study examined the role of CFP1 in maintaining liver homeostasis under conditions involving hepatocellular stress by examining liver regeneration, pregnancy-induced hepatomegaly, and non-alcoholic steatohepatitis (NASH) disease progression. The liver’s ability to recover was analyzed through liver:body mass ratios, blood serum analysis, liver histology, and qualitative observations. Deficiency of CFP1 in the livers of animals subjected to partial hepatectomies (PH) resulted in decreased liver regeneration capacity with liver mass restoration becoming significantly different starting at 48H post-PH and remaining so until 10D post-PH. This decreased regeneration appeared to be the result of reduced hepatocyte mitosis. Mouse dams lacking hepatic CFP1 mated with males expressing CFP1 displayed a proclivity for dystocia. Mice subjected to a fast food diet resulting in NASH while lacking hepatic CFP1 experienced decreased weight gain and hepatic lipid accumulation compared to their CFP1 expressing counterparts. Through these three studies, the critical role of CFP1 for the maintenance of liver homeostasis was demonstrated.

Covalent modifications of histones play a critical role in many important biological processes such as transcription, DNA repair and recombination. Among the major modifications known so far, histone H3 acetylation at lysines 9 and 14 (H3K9/14), monoubiquitination of histone H2B at lysine123 (H2BK123) and H3 lysine 4 methylation (H3K4) are among the more studied ones. The importances of these modifications have been further stressed by its connection to various human diseases including cancers. Previous biochemical studies have shown that H2BK123 ubiquitination is mandatory for methylation at histone H3K4. However, little is known about the regulatory mechanisms of H3K4 methylation by H2B ubiquitination in vivo. Thus, the prime focus of this study is to understand the factors involved in the regulation of H2B ubiquitination, the regulatory mechanisms of the cross-talk between H2BK123 ubiquitination and H3K4 methylation and the role of these covalent modifications in transcriptional regulation under physiological conditions. Here in this study, I have shown that Ubp8p, a histone deubiquitinase, is a bona fide subunit of SAGA (Spt3-Ada-Gcn5 acetyltransferase) co-activator complex and selectively regulates both di and trimethylation of histone H3K4 at the core promoter of a SAGA-dependent gene in vivo. However, over the open reading frames for a subset of constitutive genes H2B ubiquitination selectively upregulates only H3K4 trimethylation but not dimethylation. Moreover, such an upregulation of H3K4 trimethylation has no impact on the RNA Polymerase II (RNAPII) recruitment and hence transcription of the respective genes. Interestingly, at an inducible gene, histone H2B ubiquitination promotes transcription elongation independently of H3K4 methylation. Furthermore, this study also demonstrates for the first time, the molecular mechanism for the cross-talk between H2B ubiquitination and H3K4 methylation in vivo. Evidently a COMPASS subunit, Cps35p, is necessary for the trans-tail cross talk between histones H2B and H3. Finally, this study also shows that Sgf73p, a SAGA subunit, is required for SAGA recruitment at the promoters of several SAGA dependent genes and facilitates transcription in both HAT-dependent and HAT-independent manner. Collectively, the results from this study not only provide deep insights into the regulatory mechanisms of H2B ubiquitination and H3K4 methylation (and their role in transcription) but also give a new functional dimension to SAGA subunit, Sgf73p, under physiological conditions. Given the role of histone acetylation, ubiquitination and methylation in many human diseases, the results from this study is of tremendous clinical value unveiling new therapeutical targets.

Les cellules souches embryonnaires (CSE) sont un outil essentiel pour la recherche biomédicale. Elles ont à la fois la particularité de se multiplier de manière indéfinie tout en gardant leurs propriétés souches et l’incroyable capacité de donner naissance à tous les types cellulaires de l’organisme. Ces caractéristiques ouvrent de nouvelles perspectives pour la médecine régénérative mais également pour la mise au point de nouveaux essais thérapeutiques. Une des révolutions majeures reposant sur la reprogrammation cellulaire des cellules somatiques adultes en cellules souches, permet notamment d’entrevoir de nouvelles applications thérapeutiques. Les mécanismes moléculaires, tels que la méthylation de l’ADN, les modifications d’histones, et l’intervention de facteurs épigénétiques dans le remodelage de la chromatine, jouent un rôle essentiel dans la reprogrammation cellulaire et le contrôle de la pluripotence des cellules souches. L’épigénome des CSE doit non seulement maintenir l’expression des gènes associés à la pluripotence, mais également permettre une activation rapide et spécifique des gènes impliqués dans les étapes de différenciation cellulaire. Une des modifications ayant un rôle important dans l’homéostasie des CSE correspond aux méthylations d’histones H3K9 et H3K27 essentiellement associées à une répression transcriptionnelle. Ces modifications sont effectuées par des lysines méthyltransferases (HKM) dont G9a, ou bien EZH2 appartenant au complexe Polycomb PRC2. Elles recrutent également ces complexes protéiques permettant le maintien et la propagation de la modification le long du génome. Ainsi, dans ce contexte, mes travaux de thèse ont eu pour objectif de caractériser deux facteurs épigénétiques potentiels reconnaissant les histones H3K9me et H3K27me et interagissant avec le complexe PRC2. Ces études ont permis de mieux comprendre le rôle de ces protéines dans la régulation des cellules souches embryonnaires murines. Nos premières données ont montré que nos gènes candidats sont fortement exprimés dans les cellules souches embryonnaires murines (mESC) contrairement aux cellules différenciées. Par la suite, l’expression forcée d’un de ces facteurs altère la différenciation des CSE induite par le retrait de la cytokine LIF. Pour mieux comprendre comment le maintien de l’expression de notre facteur empêche la différenciation des cellules souches embryonnaires, nous avons analysé l’expression des facteurs de pluripotence Oct4, Nanog, Sox2 et Klf4. Nous avons noté un maintien de l’expression de ces facteurs ainsi que le maintien de la régulation des signaux intracellulaires intervenant en amont tels que: l’activation de la voie JAK-STAT3 pour le maintien à l’état pluripotent des ESC, et la diminution de la voie MAPK-ERK impliquée dans les processus de différenciation / Embryonic stem cells (ES cells) are an essential tool for biomedical research. They have the particularity to multiply indefinitely while keeping their stemness properties, and the incredible ability to generate all cell types of the body. These characteristics open up new perspectives for regenerative medicine but also for the development of new therapeutic trials. One of the major revolutions based on the cellular reprogramming of adult somatic cells into stem cells makes it possible to glimpse new therapeutic applications. Molecular mechanisms, such as DNA methylation, histone modifications, and the intervention of epigenetic factors in chromatin remodeling, play a critical role in cell reprogramming and pluripotency. The CSE epigenome must maintain not only the expression of genes associated with pluripotency but also allow rapid and specific activation of genes involved in cell differentiation. One of the modifications having an important role in the homeostasis of the CSE corresponds to histone methylations H3K9 and H3K27 essentially associated with transcriptional repression. These modifications are carried out by lysine methyltransferases (HKM) including G9a, or EZH2 belonging to the Polycomb PRC2 complex. They also recruit these protein complexes to maintain and propagate the change along the genome. Thus, in this context, my thesis work aimed to characterize two potential epigenetic factors recognizing histones H3K9me and H3K27me and interacting with the PRC2 complex. These studies have provided a better understanding of the role of these proteins in the regulation of murine embryonic stem cells. Our first data showed that our candidate genes are strongly expressed in murine embryonic stem cells CGR8 (mESC), unlike differentiated cells. Subsequently, the forced expression of one of these factors alters the CSE differentiation (CGR8) induced by LIF cytokine withdrawal. To better understand how maintaining the expression of our factor prevents the differentiation of embryonic stem cells, we analyzed the expression of pluripotency factors Oct4, Nanog, Sox2 and Klf4. We noted maintenance of the expression of these factors as well as the maintenance of the regulation of signals intervening upstream: including the maintenance of the activation of the JAK-STAT3 pathway for the maintenance of the pluripotent state, and the decrease of the MAPK-ERK pathway involved in differentiation processes